SHANGHAI, Dec. 7, 2018 /PRNewswire/ — NEX China, co-organized by UBM Sinoexpo and a supporter of the China’s extract industry for 10 years since its founding, will take place again in Hall E4-E5 of Shanghai New International Expo Centre (SNIEC) on June 18-20, 2019. In response to the flourishing of the international natural extract industry and resource advantages of China in the animal and plant extract field, the exhibition will be expanded to 20,000m². At the event, Chinese and overseas quality extract enterprises will appear with their innovative products. Forums and workshops related to natural raw materials will be held concurrently on site, to share information about global regulations and analyze the hottest exported varieties and application trends of natural plant extracts, so as to provide multiple solutions for the plant extract enterprises during the move toward transformation and innovation.

With the improvement of people’s living standards and the transformation of consumption structure, the focus on diseases has shifted from simple treatment to prevention in recent years. Plant extracts, as the core raw materials and products of biopharmaceuticals, have been widely applied in botanical drugs, food additives, functional foods, health foods, and cosmetics, etc. Biopharmaceuticals have developed rapidly in the 21^st century. Under new medical models, active and functional plant extract products have gained worldwide favor and broad market potential. Meanwhile, the continual introduction of favorable and industry support policies in China enables the industry to rapidly develop; the plant extract industry market size in China is expected to reach RMB 24.9 billion in 2018, and to exceed RMB 34.1 billion by 2022. The plant extract industry will become a new strategic key industry in China’s economy and social development in the future.

LIVE at 2018 Exhibition

Plant extracts enterprises to gather and open a new chapter of NEX China together

NEX China, a leading exhibition in China’s plant extract industry, has comprehensively gathered top enterprises of the industry, with the exhibitors expected to reach over 600 in 2019. In addition to the nearly 100 enterprises from Shaanxi, one of the birthplaces of plant extracts, including Acetar, Shaanxi Jiahe, Shaanxi Huike, and Xi’an Yuensun, there will also be leading plant extract enterprises from Hunan, including ACE Biotechnology, Hunan NutraMax, Hunan Huacheng, and Changsha Huir, to jointly explore the new development trends of the industry.

The China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE) has successively introduced four standards in recent years to promote the industry to gradually become normalized, driving product quality improvement and launching more advanced products and technologies at NEX China. In the exhibition this year, CCCMHPIE officially released the 2018 edition of the Plant Extract International Business Standard, which has further promoted plant extract enterprises to constantly improve extraction processes and technology to deal with industry transformation. It will normalize plant extract exports and increase China’s international competitiveness, and also bring new opportunities and challenges to the plant extract industry.

The 2019 exhibition will present diverse innovative products and technologies to buyers of the plant extract industry. For example, the technological innovation and R&D of Dongming Growth have achieved leaching of active ingredients of natural plants under low temperature conditions using ultrasonic counter-current extraction technology, which fully protects the activity of active ingredients in plants, and enables products to possess good physical properties; Xi’an App-Chem has extracted stachyose from rhizomes of Stachys sieboldii using water, which is sourced from traditional vegetables, is green and safe, has very low sweetness and calorie, and has been permitted to be used in food in many countries.

Number of Overseas Visits Grew by 50% in 2018 Exhibition

Many high-end conferences and activities on 2019 site to accelerate plant extract enterprises’ gearing toward international standards

NEX 2018 was extremely popular and attracted 60,744 visitors from 120 countries and regions together with the concurrently held CPhI China, growing by 10% over 2017; in particular, the number of overseas visitors showed explosive growth, reaching 15,329 and growing by over 50% over 2017. The numerous exhibitors expanded their stands due to the good exhibition results. NEX China 2019 will expand to cover the entire E4 and E5 Halls of SNIEC, to meet the participation demands of more enterprises.

The host will also hold many quality conferences and activities: China-World Natural Ingredient Conference 2019 will continue to analyze changes of global regulations, track standards of the United States Pharmacopeia, feel the pulse of the industry, and provide guidance for enterprises; NEX High Quality Suppliers Gallery will showcase quality plant extract suppliers that pass GEP certification and products thereof, to offer more display opportunities to Chinese quality extract plant enterprises and have more Chinese and overseas professional visitors understand the strength of Chinese enterprises; the host will also hold the Seminar on Innovative Technology for New Raw Materials in association with quality Chinese media, for in-depth conversations on new standards, new technologies, and market applications, etc., of new raw materials; furthermore, NEX China 2019 and the concurrent HNC 2019 will jointly hold the 2019 Health Product Buyer Matching Meeting, to achieve maximum resource integration, furnish exhibitors and buyers with a commerce and trade exchange platform that has higher efficiency and quality, realize an all-win scenario, and jointly help the big health industry achieve development, transformation and upgrading.

China-World Nature Ingredient Conference

Stand booking for 2019 has already begun. Visit the exhibition website http://www.cphi-china.cn/nex/en now to register online, join the annual event of the plant extract industry, and have face-to-face exchanges with well-known enterprises.

NEX China 2019
June 18-20 2019, SNIEC, Shanghai, China
Organizer: UBM EMEA, CCCMHPIE
Co-organizer: UBM Sinoexpo

Photo  – https://photos.prnasia.com/prnh/20181206/2319392-1-a
Photo  – https://photos.prnasia.com/prnh/20181206/2319392-1-b
Photo  – https://photos.prnasia.com/prnh/20181206/2319392-1-c

AHMEDABAD, India, Dec. 7, 2018 /PRNewswire/ — A consortium of growth oriented private equity investors led by CX Partners Fund 2 Limited have acquired a significant equity ownership in Veeda Clinical Research Private Limited. The investors will make additional investments in the company over a period of time to fund the growth requirements of the company.

The Board of Directors of the company will be reconstituted to have representatives from the incoming investors. Mr. Apurva Shah and Mr. Binoy Gardi, the promoters, will continue on the Board of the company and lead the management team.

Veeda is the largest independent Clinical Research Organization in India established in 2004 with its headquarters in Ahmedabad. Veeda offers a diverse range of clinical studies including healthy volunteers and patient trials for Generics, NCE and Biopharmaceuticals. Veeda is a partner of choice for many global pharmaceutical companies and is reputed for its knowledge, quality and ethics.

CX Partners Fund 2 Limited is a Mauritius-based growth oriented private equity investment fund focusing on high growth mid-market companies that are industry leaders in India. CX Partners had, from its prior Fund 1, invested in leading healthcare companies including Natco Pharma Ltd, Thyrocare Technologies Ltd and Healthium Medtech Pvt Ltd. Other past investments where CX Partners took a significant equity stake include Minacs Group, a leading Business Process Outsourcing firm, Sapphire Foods India Pvt. Ltd, a leading franchisee of Yum! Brands, Barbeque Nation Hospitality Ltd and Mrs Bectors Food Specialties Ltd.

Please contact the following for any clarifications that you may need regarding this communication:
Ms. Priyanka Tiwari
Veeda Clinical Research Private Limited
Vedant Complex, Beside YMCA Club, S. G. Highway
Vejalpur, Ahmedabad – 380 051
Gujarat India
Phone: +91-79-3001-3000
Fax: +91-79-3001-3010
Email: Priyanka.Tiwari@veedacr.com

BEIJING, Dec. 7, 2018 /PRNewswire/ — Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a leading cancer hospital operations management solutions provider and operator of a network of radiotherapy and diagnostic imaging centers in China, today announced that it will hold its 2018 annual general meeting of shareholders on December 29, 2018, at 10:00 a.m. (Beijing Time). The meeting will be held at 18/F, Tower A, Global Trade Center, 36 North 3rd Ring Road East, Dongcheng District, Beijing, China. The shareholder record date is December 17, 2018. No proposal will be submitted for shareholder approval at the annual general meeting. Instead, the annual general meeting will be convened for shareholders who are entitled to vote to discuss Company affairs with management. Concord Medical’s annual report on Form 20-F filed with the U.S. Securities and Exchange Commission, containing the Company’s audited financial statements for the financial year ended December 31, 2017, is available in the Investor Relations section of the Company’s website at http://ir.ccm.cn. The Form 20-F is also available on the SEC’s website at http://www.sec.gov.

In October 2018, Bluestone Holdings Limited (“Bluestone”), a company indirectly wholly owned by Dr. Zheng Cheng, transferred its shares in Morgancreek Investment Holdings Limited (“Morgancreek”) (which in turn held shares in Concord Medical) to companies wholly owned by Mr. Hao Zhou and Ms. Bi Zhang, the spouse of Mr. Jianyu Yang, respectively. On the same day, all the Class A Ordinary Shares of Concord Medical held by Morgancreek were converted into Class B Ordinary Shares of Concord Medical. Morgancreek transferred 7,500,000 Class B Ordinary Shares of Concord Medical to Bluestone. Upon completion of these transactions, Mr. Zhou and Ms. Zhang indirectly hold 30% and 70% shares of Morgancreek, respectively, and Dr. Cheng holds shares of Concord Medical through Bluestone. As of the date of this announcement, Morgancreek holds 38,287,948 Class B Ordinary Shares and 4,660,976 American Depositary Shares of Concord Medical, each representing three Class A ordinary shares, and Bluestone holds 7,500,000 Class B Ordinary Shares of Concord Medical. As of the date of this announcement, the Company has 84,368,529 Class A Ordinary Shares and 45,787,948 Class B Ordinary Shares issued and outstanding. Holders of Class A ordinary shares are entitled to one vote per share, while holders of Class B ordinary shares are entitled to ten votes per share.

About Concord Medical

Concord Medical Services Holdings Limited is a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China. As of June 30, 2018, the Company operated a network of 30 centers with 21 hospital partners that spanned 21 cities and 14 provinces and administrative regions in China. Under long-term arrangements with top-tier hospitals in China, the Company provides radiotherapy and diagnostic imaging equipment and manages the daily operations of these centers, which are located on the premises of its hospital partners. The Company also provides ongoing training to doctors and other medical professionals in its network of centers to ensure a high level of clinical care for patients. For more information, please see http://ir.ccm.cn.

For more information, please contact:

Concord Medical Services
Mr. Edward Zhang (Chinese and English)
+86 10 5903 6688 (ext. 608)
zhongchen.zhang@ccm.cn

View original content:http://www.prnewswire.com/news-releases/concord-medical-schedules-2018-annual-meeting-of-shareholders-300761796.html

SEOUL, South Korea, Dec. 5, 2018 /PRNewswire/ — World Institute of Kimchi, which discovers and promotes kimchi’s scientific excellence announces seven health benefits of Korea’s signature dish, Kimchi. A research team led by Professor Youn-Soo Cha at Chonbuk National University, which is one of the research teams in World Institute of Kimchi in Korea conducted an analysis of 590 research papers on kimchi (385 in Korean and 205 in English) published around the world.

According to their research, Kimchi has three components that make the dish a healthy choice. The first component is leafy vegetables such as kimchi cabbage, one of the main ingredients of kimchi. The second component is the mix of spices such as chili, one of the minor ingredients of kimchi. The last component is the byproducts of lacto-fermentation. Packed with vitamins (B1, B2, C, etc.), minerals (calcium and potassium), fiber, and lactic acid bacteria, kimchi is full of superior nutritional benefits. The bacteria found in kimchi also comes with a wide range of functionality. According to the World Institute of Kimchi, kimchi has proven effects on anti-obesity, atopic dermatitis improvement, and hair growth. It has also been found that the lactic acid bacteria found in kimchi help to prevent cancer, dyslipidemia, and high blood pressure. These bacteria have demonstrated their antioxidant properties by removing free radicals that are known to cause a variety of diseases while boosting the immune system and reducing inflammation. Understanding such advantages, the Korea’s probiotics market has achieved rapid growth by tapping into the lactic acid bacteria extracted from kimchi.

Let’s take a look at the study in addition to others from around the world and find out about the seven health benefits of kimchi.

• Allergic Diseases — Atopic Dermatitis, Asthma, Rhinitis, and More

In a study based on the outcomes of the Korea National Health and Nutrition Examination Survey (KNHANES), the prevalence of asthma decreased in people who consumed more than 40 grams of kimchi per day than in those who consumed less. According to an epidemiological study that examined the correlation between the kimchi consumption of adults aged 19 to 49 years and atopic dermatitis, the risk of atopic dermatitis was 0.68 times lower among people who ate 85–158 grams of kimchi per day than those who ate 0–36 grams. The prevalence of rhinitis was also lower by 0.81 times in people who included 108–180 grams of kimchi in their diet per day than those who only ate 0–23.7 grams. In 2017, the World Institute of Kimchi found that lactic acid bacteria (Weissella cibaria WIKIM28) isolated from kimchi have extraordinary effects in preventing and improving atopic dermatitis. The kimchi strain was given to atopic-dermatitis-induced mice to analyze the change in various immune system indicators; the serum levels of the IgE that triggers atopic dermatitis were reduced by approximately 50% while dermatitis symptoms were reduced by approximately 40%.

• Anticancer

One of the reasons for high expectations over kimchi as an anticancer dish is its vegetable ingredients, which consist of kimchi cabbage, radish, mustard leaf, garlic, and chili — vegetables known to prevent cancer. The anticancer compounds found in kimchi include indole-3-carbinol (kimchi cabbage), isothiocyanate (kimchi cabbage), allyl sulfide (garlic), and capsaicin (chili powder). They are the reason that experts expect kimchi to be beneficial for inhibiting stomach, liver, colon, lung, and bladder cancers. The Rural Development Administration, a Korean government agency, reported that kimchi offers greater anticancer effects when it is adequately aged. Mixed with spices such as garlic, ginger, chili powder, and a local variety of scallion, a batch of kimchi was aged sufficiently, which was added to a gastric cancer cell line (MKN45). It was found to be 4–10 percent more effective in suppressing the growth of cancer cells than unfermented kimchi was. Further, it was found that chili powder suppressed cancer cell growth more than other types of spices, followed by garlic.

• Enhanced Digestion

Another reason that makes kimchi so attractive is that it enhances digestion, cleans up the gut, and restores gut health thanks to the healthy lactic acid bacteria generated in the fermentation process. In the past, it was believed that the kimchi bacteria die before they reach the gut because of the acid in the stomach. However, a study by the Kimchi Research Institute at Pusan National University revealed that the daily consumption of 300 grams of kimchi increased the bacteria in the colon by 100 times compared to those who do not eat kimchi.

• Anti-obesity

Kimchi is remarkable that it saves appetite but does not make fat. Kimchi has as few as 9 kilocalories (dongchimi) and as many as 55 kilocalories (scallion kimchi) per 100 grams. Kimchi made with kimchi cabbage has only 29 kilocalories. Capsaicin, which makes chili spicy, helps to break down and burn fat. Dietary fiber in kimchi helps with early satiation and aids bowel movement. A recent study by the World Institute of Kimchi revealed that after adding the bacteria strain isolated from kimchi (Lactobacillus sakei), the differentiation of fat cells was suppressed and body fat was reduced in mice that were used as obesity-induced models with a high-fat diet.

• Suppression of Pathogenic Bacteria

Kimchi is famous for its antibacterial properties, killing pathogenic bacteria that cause food poisoning. This is also because of lactic acid bacteria, which inhibit the proliferation of harmful bacteria that may exist in kimchi. As kimchi ferments, lactic acid bacteria proliferate and produce lactic acid, thereby lowering the pH naturally. A study by the World Institute of Kimchi indicates that the level of coliforms was approximately 17,000 CFU (colony-forming unit) in a gram of kimchi in the early phase of fermentation, with a pH of 5.8. As fermentation progressed (at 4℃ 8 weeks later), kimchi dropped in pH to 4.1, with all coliforms annihilated.

• Prevention of Anemia

Adult males who consumed 300 grams of kimchi daily for four weeks showed a spike in the serum levels of iron and ferritin, which helps the absorption of iron. This indicates that kimchi may be helpful in preventing anemia, which is mainly caused by iron deficiency.

• Prevention of Vascular Diseases

In a study, healthy adults were asked to take 30 grams of tablets made of freeze-dried kimchi every day for six weeks. The result showed that their triglyceride levels in the blood and atherogenic index decreased while the HDL cholesterol level, a good cholesterol for vascular health, increased.

About World Institute of Kimchi

The Korean government established World Institute of Kimchi in January 2010, the only kimchi research facility in the world to promote and introduce the distinctive excellence of kimchi based on scientific evidence. A government-funded research institute established to perform research and development related to kimchi, to lead national technological innovation, nature and develop the kimchi industry that will boost the national growth. It performs overall research and development related to kimchi, in order to lead national technological innovation and nurture and develop the kimchi industry that will boost the national growth.

View original content:http://www.prnewswire.com/news-releases/world-institute-of-kimchi-seven-health-benefits-of-koreas-signature-dish-kimchi-300760311.html

SEOUL, South Korea, Dec. 3, 2018 /PRNewswire/ — Gencurix, the developer of a molecular diagnostic test, GenesWell™ BCT, reported another evidence for the efficacy of the product.

GenesWell(TM) BCT full set

GenesWell™ BCT is a gene expression profiling test that predicts probability of distant metastasis and recurrence rate within 10 years in patients with HER2-negative, lymph node-negative, and hormone receptor-positive(ER+ and/or PR+) early stage breast cancer.

The additional clinical research shows that patients who are identified as high-risk by GenesWell™ BCT had increased survival rate after undergoing chemotherapy; the research has been published in ‘PLOS ONE’, published by the Public Library of Science of the U.S. (Citation: Kwon MJ, Lee SB, Han J, Lee JE, Lee JW, Gong G, et al. (2018) BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer. PLOS ONE 13(11): e0207155; https://doi.org/10.1371/journal.pone.0207155).

The result of this new study showed that the patients classified as low risk according to the BCT score had good prognosis with only hormone therapy. There was no significant difference in 10 year distant metastasis free survival (DMFS) between patients treated with hormone therapy plus chemotherapy and those treated with hormone therapy alone. However, the high–risk patients treated with hormone therapy plus chemotherapy showed higher 10 year DMFS than those treated with hormone therapy alone.

GenesWell™ BCT has been approved by Ministry of Food and Drug Safety(MFDS) and received a lot of attention when the clinical evidences of 400 Korean breast cancer patients was published in Scientific Reports, a sister journal of the Nature. Currently, they are planning joint clinical study collaborating with hospitals in Japan.

“GenesWell™ BCT is the first products that completed clinical trial with Asian patients, reflecting the genetic and environmental characteristics of Asians.” Sangrae Cho, CEO of Gencurix, said in a statement announcing the publication of the study results. “It is of great significance to have objectively proved that the BCT score is not only of prognostic value, but is also a predictor of chemotherapy benefit for early breast cancer,” he added.

Gencurix has been selected as one of Hi Seoul Brand Company in 2017. Recently, GenesWell™ ddEGFR Mutation Test, the test that detects EGFR mutation for non-small cell lung cancer, has been approved by MFDS. It is about to hit the Asian market including Japan.

Photo – https://photos.prnasia.com/prnh/20181203/2315344-1

CHANGZHOU, China, Dec. 5, 2018 /PRNewswire/ — Changzhou Qianhong Bio-pharma Co., Ltd. started construction of the phase two of pharmaceuticals production facility at Changzhou National Hi-Tech District on November 28. With an investment of 1 billion yuan, phase two adds 200 million tablets and 60 million injections to production as well as making molecular diagnosis reagents available for use by 20 million people. Changzhou government officials including Liang Yibo and Yan Jun took part in the groundbreaking ceremony.

The groundbreaking ceremony for Changzhou Qianhong Bio-pharma’s phase two pharmaceuticals production facility

Changzhou Qianhong Bio-pharma, a leading biochemical maker of polysaccharides and enzymes drugs, has won numerous awards for its high quality and integrity for years. Changzhou Qianhong Bio-pharma was listed on the Shenzhen Stock Exchange on February 18, 2011 (Changzhou Qianhong Bio-pharma; stock code: 002550). The company is a major manufacturer of pancreatic kininogenase, heparin sodium and low molecular weight heparin, as well as compound digestive enzyme preparations and asparaginase, all of which had, prior to the roll out of the phase one facility, never been produced in China. The entire drug lineup meets international standards in terms of production technologies and quality. Several products have been granted quality certifications by governing bodies in the US, the EU and Japan. The company has set up a comprehensive international marketing network, with products being sold in more than 20 provinces and cities across China as well as exported to markets abroad.

The 1.2 billion-yuan phase one project, which is already in operation, generated sales revenue of 1,070 million yuan in 2017. Phase two, in line with international standards, will focus on the research and development of innovative and first-of-its-class-in-China biological drugs with its own intellectual property rights, with the aim of treating patients with critical illnesses such as cancers as well as cardiovascular and cerebrovascular diseases.

Photo – https://photos.prnasia.com/prnh/20181129/2312966-1

Source: Panther Orthopedics, Inc.

Source: AGC Inc.

SHANGHAI, Dec. 4, 2018 /PRNewswire/ — Regulation and standards for “clean plants” have been increasing in recent years as China’s pharmaceutical R&D and production industry develops rapidly. EP & Clean Tech China 2019, hosted by CCCMHPI, UBM EMEA and UBM Sinoexpo, is an annual event of the pharma clean industry, that will blow a strong, new pharma clean wind in Hall N4 of Shanghai New International Expo Centre (SNIEC). Over 100 Chinese and overseas quality clean enterprises will gather on-site, to showcase the latest pharma cleanroom equipment and products, engineering technologies, and solutions, etc.

A super-large exhibition area, and an appearance of clean brands

The new session of EP & Clean Tech China will take place at SNIEC Shanghai, China on June 18-20, 2019. Occurring concurrently with P-MEC China, CPhI China and bioLIVE China, the show will cover all the 17 exhibition halls of SNIEC, with a total of 200,000m² exhibition area, and welcome over 3,200 exhibitors and more than 50,000 Chinese and overseas professional visitors, to jointly participate in the annual event of the pharmaceutical industry.

Over 100 Chinese and overseas exhibitors represented by Dynaco, Gusu, MAX, Sinoarch, Linsen, and Sujing, etc. will showcase their newly upgraded purification products and equipment, project cases and solutions. They will bring an international, high-quality annual event of the pharmaceutical and clean industries for over 50,000 professionals relating to procurement, project, and cleanness of pharmaceutical enterprises on the site.

Top Brands

Gathering global professional buyers, and running through the pharmaceutical industry chain

EP & Clean Tech China 2019 will take root in the pharmaceutical industry, and gather relevant industry professionals from pharmaceutical industry chains, including APIs, fine chemical and intermediate, pharmaceutical excipients, preparations, contract research, biopharmaceuticals, natural extracts, and animal health and feed, etc. It will become an excellent platform to showcase pharmaceutical green production, and clean technical equipment and projects. Furthermore, the exhibition will become more international to attract international buyers. In 2018 exhibition, proportions of visitors from Asia (excluding China), Europe, and America separately accounted for 76%, 14%, and 7%, with proportions of European and American buyers rising again.

Visitor Job Title & Purchasing Power Analysis

High-end technology forum and buyer matching meetings, to help seize early opportunities of the industry

The “Pharma Cleanroom Technology Forum 2019” will gather an audience of 100+ people from pharmaceutical enterprises and biotechnology industry and focus on hot topics such as energy conservation and high efficiency, and innovative clean equipment. The forum in 2018 attracted heads of procurement, R&D, and quality departments from well-known pharmaceutical enterprises, including Fosun Pharma, Shanghai Pharma, Sinopharm, Weikang Pharmaceuticals, Zhuhai United Laboratories, Bayer, Merck Chemicals, and WuXi AppTec, etc.

Pharma Cleanroom Technology Forum

Furthermore, the host will hold the “EP & Clean Tech Buyers Sourcing Event and Discovery Tour” to meet the needs of pharmaceutical plants with recent plans for new plant construction, plant renovation, and equipment upgrading. The event is expected to gather nearly 20 Chinese and overseas interested buyers, match suppliers and Chinese and overseas buyers precisely, and give them a closer look at the simulated cleanroom, clean equipment, and project stands.

EP & Clean Tech Buyers Sourcing Event and Discovery Tour

EP & Clean Tech China 2019 will continue to furnish pharmaceutical enterprises and professionals from biopharmaceuticals, clean project, and clean equipment industries, etc. with a diversified communication platform that connects “exhibition” and “conferences”. Please visit http://en.pmecchina.com/ for more information.

2019 EP & Clean Tech China
18-20 June, 2019 | SNIEC Shanghai, China
Add: No.2345 Longyang Road, Pudong New District, Shanghai, China
http://en.pmecchina.com/

Photo – https://photos.prnasia.com/prnh/20181203/2314130-1-a
Photo – https://photos.prnasia.com/prnh/20181203/2314130-1-b
Photo – https://photos.prnasia.com/prnh/20181203/2314130-1-c
Photo – https://photos.prnasia.com/prnh/20181203/2314130-1-d

FIDO and Egis Technology co-organized the event

TAIPEI, Taiwan, Dec. 3, 2018 /PRNewswire/ — 2018 FIDO Taipei Seminar, jointly organized by the FIDO (Fast Identity Online) Alliance and Egis Technology Inc., was held in Taipei on Nov. 30. Themed “No More Passwords”, the event brought together professionals from around the world to discuss updates and future trends in authentication and identification technologies with the aim of encouraging Taiwanese stakeholders and government departments to adopt the technologies in line with international standards. Adoption of such technologies opens the way to more business opportunities.

2018 FIDO Taipei Seminar bringing together professionals and government officials from around the world; key speakers including Steve Ro, Chairman of Egis Technology; Zse-Hong Tsai, Executive Secretary of Office of Board of Science and Technology; Brett McDowell, Executive Director of FIDO Alliance, and legislator Jason Hsu

The event’s key speakers included Egis Technology COO Todd Lin, Office of Board of Science and Technology executive secretary Zse-Hong Tsai, legislator Jason Hsu and Chinese Taipei PKI & e-Authentication Consortium chair Che-Ho Wei.

Todd said during his speech that as a board member of FIDO, Egis is committed to broadening Taiwan’s international presence via international partnerships and is glad to see increased interest on behalf of stakeholders and the government in authentication and identification applications. FIDO is an industry consortium whose mission is to provide alternatives to passwords in a move to increase network security, while helping companies and organizations cut deployment costs. FIDO wants to heighten interest among Taiwanese government departments and stakeholders in the technologies and facilitate their widespread adoption across the Taiwan via the seminar, in a bid to make Taiwan a better, more convenient and safer place to live.

Brett McDowell, Executive Director of FIDO Alliance, gave a brief presentation on the alliance and its operations. FIDO aims to develop specifications that define an open and interoperable set of mechanisms to supplant reliance on passwords in a way that securely authenticates users of online services via technologies such as biometric authentication and security modules. The 250+ member, cross-industry FIDO has received an enthusiastic response from leading international firms. Its two sets of specifications, U2F and UAF, have been widely deployed in China, Japan and South Korea. The alliance has also set up a win-win ecosystem with global partners. The FIDO2 Project continues to expand its reach, with international organizations such as W3C and ITU adopting its recommendations. Brett also shared encouraging news with attendees at the event: On November 28, ITU announced adoption of FIDO2 as part of its international specifications. The original FIDO had already been part of the specifications.

Sessions in the morning included FIDO2 case studies presented by Early Warning Service and Microsoft, followed by case studies in Taiwan presented by GoTrust, AuthenTrend, TWCA and Kiwi Technology. GoTrust assisted a Taiwanese bank in implementing the FIDO solution into its mobile app, leading to the number of transactions being handled through the app tripling while overall utilization doubled, thanks to the convenience and added security. AuthenTrend’s ATKey.Card, with a built-in USB, Bluetooth Low Energy (BLE), Near Field Communication (NFC) and single-fingerprint enabled authenticator, works for all devices including PCs and can be used as an employee ID badge and location tracker. Kiwi Technology uses FIDO authentication as a key management solution to increase the security of IoT applications.

To bring local attendees up to date on the latest global trends and FIDO’s widespread adoption across Asia, during the afternoon session, guests from South Korea, Japan, Thailand and India related the progress of FIDO in their respective countries.

Dongpyo Hong, Vice Chairman of FIDO Korea WG, said 31 South Korea-based firms have joined FIDO, making South Korea the leader in terms of the number of companies building FIDO certified products. Since 2013, FIDO specifications have been deployed in the financial, telecom and education sectors as well as in many firms and government departments. Leading Korea-based companies, among them Samsung Electronics, BC Card, SK Planet and KT, have enhanced their quality of service and user experience via deployment of FIDO standards. Looking forward, a FIDO standards-based integrated certification platform is on schedule to be built and expanded to IoT and blockchain applications.

Koichi Moriyama, Senior Director of Product Innovation in NTT DOCOMO and Chairman of FIDO Japan WG, gave a presentation on NTT DOCOMO’s FIDO Universal Authentication Framework (UAF). To help users who often forget their passwords, NTT DOCOMO advocates adoption of a FIDO UAF specification to deliver a password-less experience, where a user is able to use a form of biometric authentication on their local device, such as a fingerprint or an iris scan to securely log in. In addition to integrating FIDO UAF into its dmarket service. In 2015, NTT DOCOMO had taken the lead in launching UAF-certified devices and servers. He emphasized that FIDO is the best solution in terms of cost, usage, security and range of applications and that NTT DOCOMO plans to further expand FIDO UAF-certified products into all new Android devices.

IC Liu, CEO of Next Bank Preparation Office, moderated a panel discussion, the last session of the seminar. Themed “How Taiwan/Asia Embrace the World,” Taipei City Government Department of Information Technology director Wei-Bin Lee, Taiwan Association of Information and Communication Standards (TAICS) secretary general Sheng-Lin Chou, FIDO Alliance executive director Brett McDowell, Asia PKI Consortium (APKIC) representative Dr. Soranun Jiwasurat and legislator Jason Hsu discussed how Taiwan should embrace the new technologies and establish a firm footprint in Asia and even the world in terms of standards, ICT, and culture.

Photo – https://photos.prnasia.com/prnh/20181130/2314065-1
Logo – https://photos.prnasia.com/prnh/20180307/2074033-1LOGO

Source: Egis Technology Inc.